xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05966857</url>
    </required_header>
    <id_info>
      <org_study_id>66520122.0.0000.0068</org_study_id>
      <nct_id>NCT05966857</nct_id>
    </id_info>
    <brief_title>FAPO-X: Assisted Digital Telemonitoring With Wearables in Patients After Cardiovascular Surgery</brief_title>
    <acronym>FAPO-X</acronym>
    <official_title>FAPO-X: Assisted Digital Telemonitoring With Wearables in Patients After Cardiovascular Surgery</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>University of Sao Paulo</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Samsung Electronics</agency>
        <agency_class>Industry</agency_class>
      </collaborator>
    </sponsors>
    <source>University of Sao Paulo</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This study aims to develop a digitally assisted telemonitoring platform using the Samsung TM&#xD;
        Galaxy Watch5 smartwatch, validating the applicability of the solution in patients with POAF&#xD;
        (Postoperative Atrial Fibrillation), along with the accuracy of the smartwatch in detecting&#xD;
        vital signs through optical sensors and possibly identifying irregularities in heart rhythm.&#xD;
        The validation of its applicability will be carried out through a clinical trial. This is a&#xD;
        randomized observational pilot study resulting from the partnership established in the base&#xD;
        year of 2022 between InCor and Samsung.&#xD;
  &#xD;
        The sample consisted of 108 outpatient patients with cardiac diseases who underwent cardiac&#xD;
        surgery and were selected during the preoperative consultation. Subsequently, the patients&#xD;
        were randomized (1:1) into the intervention group (teleassisted group) or the control group&#xD;
        (standard institution follow-up).&#xD;
  &#xD;
        The sample size was proposed by the contracting party as this is a pilot study to assess&#xD;
        whether the implementation of a technological solution assists in monitoring and predicting&#xD;
        the risk of surgical patients in the postoperative phase, as well as the accuracy of the&#xD;
        Samsung TM Galaxy Watch5 smartwatch in a sample with POAF.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This interventional study was conducted exclusively at the Heart Institute of the Clinics&#xD;
        Hospital of the Medical School of the University of São Paulo (InCor - HCFMUSP). It was a&#xD;
        single-center study divided into six phases.&#xD;
  &#xD;
        The first phase involved outpatient preoperative care, where patients underwent a&#xD;
        comprehensive anamnesis during the preoperative consultation and were informed about the&#xD;
        study. In the second phase, patients were hospitalized and provided with the Informed Consent&#xD;
        Form (ICF) if they met the inclusion criteria. Demographic data were collected during this&#xD;
        phase.&#xD;
  &#xD;
        During the surgical phase (third phase), intraoperative data were collected after cardiac&#xD;
        surgery. The fourth phase focused on postoperative care, where patients were evaluated, and&#xD;
        health measures such as blood pressure (BP), heart rate (HR), electrocardiogram (ECG), and&#xD;
        peripheral oxygen saturation (SpO2) were collected using the SAMSUNGTM Galaxy Watch5&#xD;
        smartwatch and reference devices.&#xD;
  &#xD;
        After discharge, the fifth phase involved a 30-day telemonitoring period, where patients were&#xD;
        remotely monitored using the smartwatch. Health data, including BP, HR, ECG, and SpO2, were&#xD;
        collected three times a day during this phase. The medical team provided clinical&#xD;
        interventions when alerts were received via the &quot;FAPO SI³&quot; platform.&#xD;
  &#xD;
        In the final phase, patients returned for an outpatient visit at InCor, where health measures&#xD;
        were collected again using the smartwatch and reference devices. Additionally, a World Health&#xD;
        Organization Quality of Life (WHOQOL) questionnaire was administered to assess patients'&#xD;
        quality of life. ECG reports issued by the smartwatch were also reviewed.&#xD;
  &#xD;
        The control group consisted of patients with heart disease who underwent surgical procedures&#xD;
        and received standard outpatient and post-surgical follow-up according to institutional&#xD;
        routines and protocols.&#xD;
  &#xD;
        Overall, the study aimed to develop and validate an assisted digital telemonitoring platform&#xD;
        for patients with postoperative atrial fibrillation (POAF). The telemonitored group used the&#xD;
        SAMSUNGTM Galaxy Watch5 smartwatch for remote monitoring, while the control group followed&#xD;
        standard care protocols.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Completed</overall_status>
    <start_date type="Actual">February 17, 2023</start_date>
    <completion_date type="Actual">May 23, 2023</completion_date>
    <primary_completion_date type="Actual">May 23, 2023</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>This interventional study utilized a parallel assignment model to develop and validate an assisted digital telemonitoring platform for patients with POAF. The telemonitored group received interventions and telemonitoring through the platform, while the control group followed the standard institutional patient journey without any intervention or telemonitoring.</intervention_model_description>
      <primary_purpose>Health Services Research</primary_purpose>
      <masking>Single (Outcomes Assessor)</masking>
      <masking_description>During the 30-day telemonitoring period in the TLM (Telemonitoring) group, the ECG report evaluator was blinded to the patient's clinical condition and the presence of underlying atrial fibrillation (AF).&#xD;
  This masking approach was adopted to ensure that the evaluator was not influenced by prior clinical information or knowledge of the presence of AF before analyzing the ECG results provided by the smartwatch. The objective is to ensure impartiality and objectivity in the evaluation of the data obtained during the telemonitoring period.&#xD;
  By keeping this information hidden from the evaluator, a more unbiased and accurate analysis of the results can be achieved, without the influence of prior knowledge about the patient's clinical condition or the presence of AF. This contributes to ensuring the validity and reliability of the results obtained through smartwatch telemonitoring in the TLM group.</masking_description>
    </study_design_info>
    <primary_outcome>
      <measure>Rehospitalization rate</measure>
      <time_frame>30-day</time_frame>
      <description>Frequency (n, %)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Scheduled consultations</measure>
      <time_frame>30-day</time_frame>
      <description>Frequency (n, %)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Extra occurences</measure>
      <time_frame>30-day</time_frame>
      <description>Frequency (n, %)</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Technological adherence</measure>
      <time_frame>30-day</time_frame>
      <description>Frequency (n, %)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Treatment adherence</measure>
      <time_frame>30-day</time_frame>
      <description>Frequency (n, %)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Use of the mobile application by patients</measure>
      <time_frame>30-day</time_frame>
      <description>Frequency (n, %)</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Actual">108</enrollment>
    <condition>Heart; Surgery, Heart, Functional Disturbance as Result</condition>
    <arm_group>
      <arm_group_label>Control Group (CTL)</arm_group_label>
      <arm_group_type>No Intervention</arm_group_type>
      <description>Patients who underwent standard treatment at the institution without any wearable monitoring.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Telemonitored Group (TLM)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Patients who received telemonitoring with a Samsung Galaxy smartwatch and FAPO SI³ platform, which is integrated with the hospital's electronic medical record system.</description>
    </arm_group>
    <intervention>
      <intervention_type>Device</intervention_type>
      <intervention_name>Wearable: Smartwatch</intervention_name>
      <description>The SAMSUNGTM Galaxy Watch5 Smartwatch, is a new generation of smartwatches, features an innovative 3-in-1 BioActive sensor, which uses a chip to capture optical and read cardiac electrical current, allowing to carry out high-quality real-time single-lead electrocardiogram. Despite the more compact design, there is no decrease in accuracy. These signals are then processed by the device's algorithms and can be sent to a trained professional for evaluation immediately after the measurement, facilitating the monitoring and diagnosis of arrhythmias.</description>
      <arm_group_label>Telemonitored Group (TLM)</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Age ≥ 22 years;&#xD;
  &#xD;
            -  Parameters for surgical indication, in the presence of heart disease (mitral or aortic&#xD;
               valve disease, coronary artery disease or aortic disease);&#xD;
  &#xD;
            -  Agree to adhere to the study's procedures and requirements;&#xD;
  &#xD;
            -  Be able to consent to their participation in writing;&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Not having undergone cardiac surgery;&#xD;
  &#xD;
            -  Presence of post-surgical complications with prolonged hospital stay for more than 14&#xD;
               days from surgery date;&#xD;
  &#xD;
            -  Presence of a Peripherally Inserted Central Catheter (PICC) or limb preservation and&#xD;
               cardiac pacemaker in case of impediment to acquisition of the ECG (smartwatch);&#xD;
  &#xD;
            -  Patients with arteriovenous fistula;&#xD;
  &#xD;
            -  Presence of skin pathology or skin diseases such as vitiligo, lupus and atopic&#xD;
               dermatitis, as well as tattoos in the wrist region, which may interfere with the&#xD;
               reading by the optical sensor;&#xD;
  &#xD;
            -  Show sensitivity or allergic reactions, to any degree, to the component materials of&#xD;
               the wearable device;&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>22 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <location>
      <facility>
        <name>Instituto do Coracao (Heart Institute), Faculdade de Medicina, Hospital das Clinicas, Universidade de Sao Paulo</name>
        <address>
          <city>Sao Paulo</city>
          <state>SP</state>
          <zip>05403-900</zip>
          <country>Brazil</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>Brazil</country>
    </location_countries>
    <results_reference>
      <citation>Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021 Feb;16(2):217-221. doi: 10.1177/1747493019897870. Epub 2020 Jan 19. Erratum In: Int J Stroke. 2020 Jan 28;:1747493020905964.</citation>
      <PMID>31955707</PMID>
    </results_reference>
    <results_reference>
      <citation>Albini A, Malavasi VL, Vitolo M, Imberti JF, Marietta M, Lip GYH, Boriani G. Long-term outcomes of postoperative atrial fibrillation following non cardiac surgery: A systematic review and metanalysis. Eur J Intern Med. 2021 Mar;85:27-33. doi: 10.1016/j.ejim.2020.12.018. Epub 2021 Jan 2.</citation>
      <PMID>33402281</PMID>
    </results_reference>
    <results_reference>
      <citation>Lopes LA, Agrawal DK. Post-Operative Atrial Fibrillation: Current Treatments and Etiologies for a Persistent Surgical Complication. J Surg Res (Houst). 2022;5(1):159-172. doi: 10.26502/jsr.10020209. Epub 2022 Mar 28.</citation>
      <PMID>35445200</PMID>
    </results_reference>
    <results_reference>
      <citation>Goulden CJ, Hagana A, Ulucay E, Zaman S, Ahmed A, Harky A. Optimising risk factors for atrial fibrillation post-cardiac surgery. Perfusion. 2022 Oct;37(7):675-683. doi: 10.1177/02676591211019319. Epub 2021 May 26.</citation>
      <PMID>34034586</PMID>
    </results_reference>
    <results_reference>
      <citation>Phan K, Ha HS, Phan S, Medi C, Thomas SP, Yan TD. New-onset atrial fibrillation following coronary bypass surgery predicts long-term mortality: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2015 Dec;48(6):817-24. doi: 10.1093/ejcts/ezu551. Epub 2015 Jan 18.</citation>
      <PMID>25602053</PMID>
    </results_reference>
    <results_reference>
      <citation>Baig MM, GholamHosseini H, Moqeem AA, Mirza F, Linden M. A Systematic Review of Wearable Patient Monitoring Systems - Current Challenges and Opportunities for Clinical Adoption. J Med Syst. 2017 Jul;41(7):115. doi: 10.1007/s10916-017-0760-1. Epub 2017 Jun 19.</citation>
      <PMID>28631139</PMID>
    </results_reference>
    <results_reference>
      <citation>Tison GH, Sanchez JM, Ballinger B, Singh A, Olgin JE, Pletcher MJ, Vittinghoff E, Lee ES, Fan SM, Gladstone RA, Mikell C, Sohoni N, Hsieh J, Marcus GM. Passive Detection of Atrial Fibrillation Using a Commercially Available Smartwatch. JAMA Cardiol. 2018 May 1;3(5):409-416. doi: 10.1001/jamacardio.2018.0136.</citation>
      <PMID>29562087</PMID>
    </results_reference>
    <results_reference>
      <citation>Chandrasekaran R, Katthula V, Moustakas E. Patterns of Use and Key Predictors for the Use of Wearable Health Care Devices by US Adults: Insights from a National Survey. J Med Internet Res. 2020 Oct 16;22(10):e22443. doi: 10.2196/22443.</citation>
      <PMID>33064083</PMID>
    </results_reference>
    <results_reference>
      <citation>Nachman D, Gilan A, Goldstein N, Constantini K, Littman R, Eisenkraft A, Grossman E, Gepner Y. Twenty-Four-Hour Ambulatory Blood Pressure Measurement Using a Novel Noninvasive, Cuffless, Wireless Device. Am J Hypertens. 2021 Nov 20;34(11):1171-1180. doi: 10.1093/ajh/hpab095.</citation>
      <PMID>34143867</PMID>
    </results_reference>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 7, 2023</study_first_submitted>
    <study_first_submitted_qc>July 20, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 1, 2023</study_first_posted>
    <last_update_submitted>July 20, 2023</last_update_submitted>
    <last_update_submitted_qc>July 20, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 1, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
      <investigator_full_name>Fabio Biscegli Jatene</investigator_full_name>
      <investigator_title>MD, PhD</investigator_title>
    </responsible_party>
    <provided_document_section>
      <provided_document>
        <document_type>Study Protocol and Statistical Analysis Plan</document_type>
        <document_has_protocol>Yes</document_has_protocol>
        <document_has_icf>No</document_has_icf>
        <document_has_sap>Yes</document_has_sap>
        <document_date>January 7, 2023</document_date>
        <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT05966857/Prot_SAP_000.pdf</document_url>
      </provided_document>
      <provided_document>
        <document_type>Informed Consent Form</document_type>
        <document_has_protocol>No</document_has_protocol>
        <document_has_icf>Yes</document_has_icf>
        <document_has_sap>No</document_has_sap>
        <document_date>January 7, 2023</document_date>
        <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT05966857/ICF_001.pdf</document_url>
      </provided_document>
    </provided_document_section>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05966857
  org study id: 66520122.0.0000.0068
  nct id: NCT05966857
  lead sponsor: 
  collaborator: 
  is fda regulated drug: No
  is fda regulated device: No
  This study aims to develop a digitally assisted telemonitoring platform using the Samsung TM
        Galaxy Watch5 smartwatch, validating the applicability of the solution in patients with POAF
        (Postoperative Atrial Fibrillation), along with the accuracy of the smartwatch in detecting
        vital signs through optical sensors and possibly identifying irregularities in heart rhythm.
        The validation of its applicability will be carried out through a clinical trial. This is a
        randomized observational pilot study resulting from the partnership established in the base
        year of 2022 between InCor and Samsung.
  
        The sample consisted of 108 outpatient patients with cardiac diseases who underwent cardiac
        surgery and were selected during the preoperative consultation. Subsequently, the patients
        were randomized (1:1) into the intervention group (teleassisted group) or the control group
        (standard institution follow-up).
  
        The sample size was proposed by the contracting party as this is a pilot study to assess
        whether the implementation of a technological solution assists in monitoring and predicting
        the risk of surgical patients in the postoperative phase, as well as the accuracy of the
        Samsung TM Galaxy Watch5 smartwatch in a sample with POAF.
  This interventional study was conducted exclusively at the Heart Institute of the Clinics
        Hospital of the Medical School of the University of São Paulo (InCor - HCFMUSP). It was a
        single-center study divided into six phases.
  
        The first phase involved outpatient preoperative care, where patients underwent a
        comprehensive anamnesis during the preoperative consultation and were informed about the
        study. In the second phase, patients were hospitalized and provided with the Informed Consent
        Form (ICF) if they met the inclusion criteria. Demographic data were collected during this
        phase.
  
        During the surgical phase (third phase), intraoperative data were collected after cardiac
        surgery. The fourth phase focused on postoperative care, where patients were evaluated, and
        health measures such as blood pressure (BP), heart rate (HR), electrocardiogram (ECG), and
        peripheral oxygen saturation (SpO2) were collected using the SAMSUNGTM Galaxy Watch5
        smartwatch and reference devices.
  
        After discharge, the fifth phase involved a 30-day telemonitoring period, where patients were
        remotely monitored using the smartwatch. Health data, including BP, HR, ECG, and SpO2, were
        collected three times a day during this phase. The medical team provided clinical
        interventions when alerts were received via the "FAPO SI³" platform.
  
        In the final phase, patients returned for an outpatient visit at InCor, where health measures
        were collected again using the smartwatch and reference devices. Additionally, a World Health
        Organization Quality of Life (WHOQOL) questionnaire was administered to assess patients'
        quality of life. ECG reports issued by the smartwatch were also reviewed.
  
        The control group consisted of patients with heart disease who underwent surgical procedures
        and received standard outpatient and post-surgical follow-up according to institutional
        routines and protocols.
  
        Overall, the study aimed to develop and validate an assisted digital telemonitoring platform
        for patients with postoperative atrial fibrillation (POAF). The telemonitored group used the
        SAMSUNGTM Galaxy Watch5 smartwatch for remote monitoring, while the control group followed
        standard care protocols.
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: This interventional study utilized a parallel assignment model to develop and validate an assisted digital telemonitoring platform for patients with POAF. The telemonitored group received interventions and telemonitoring through the platform, while the control group followed the standard institutional patient journey without any intervention or telemonitoring.
  primary purpose: Health Services Research
  masking: Single (Outcomes Assessor)
  masking description: During the 30-day telemonitoring period in the TLM (Telemonitoring) group, the ECG report evaluator was blinded to the patient's clinical condition and the presence of underlying atrial fibrillation (AF).
  This masking approach was adopted to ensure that the evaluator was not influenced by prior clinical information or knowledge of the presence of AF before analyzing the ECG results provided by the smartwatch. The objective is to ensure impartiality and objectivity in the evaluation of the data obtained during the telemonitoring period.
  By keeping this information hidden from the evaluator, a more unbiased and accurate analysis of the results can be achieved, without the influence of prior knowledge about the patient's clinical condition or the presence of AF. This contributes to ensuring the validity and reliability of the results obtained through smartwatch telemonitoring in the TLM group.
  measure: Rehospitalization rate
  time frame: 30-day
  description: Frequency (n, %)
  measure: Scheduled consultations
  time frame: 30-day
  description: Frequency (n, %)
  measure: Extra occurences
  time frame: 30-day
  description: Frequency (n, %)
  measure: Technological adherence
  time frame: 30-day
  description: Frequency (n, %)
  measure: Treatment adherence
  time frame: 30-day
  description: Frequency (n, %)
  measure: Use of the mobile application by patients
  time frame: 30-day
  description: Frequency (n, %)
  arm group label: Control Group (CTL)
  arm group type: No Intervention
  description: Patients who underwent standard treatment at the institution without any wearable monitoring.
  arm group label: Telemonitored Group (TLM)
  arm group type: Experimental
  description: Patients who received telemonitoring with a Samsung Galaxy smartwatch and FAPO SI³ platform, which is integrated with the hospital's electronic medical record system.
  intervention type: Device
  intervention name: Wearable: Smartwatch
  description: The SAMSUNGTM Galaxy Watch5 Smartwatch, is a new generation of smartwatches, features an innovative 3-in-1 BioActive sensor, which uses a chip to capture optical and read cardiac electrical current, allowing to carry out high-quality real-time single-lead electrocardiogram. Despite the more compact design, there is no decrease in accuracy. These signals are then processed by the device's algorithms and can be sent to a trained professional for evaluation immediately after the measurement, facilitating the monitoring and diagnosis of arrhythmias.
  arm group label: Telemonitored Group (TLM)
  criteria: 
  gender: All
  minimum age: 22 Years
  maximum age: N/A
  healthy volunteers: No
  facility: 
  country: Brazil
  citation: Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021 Feb;16(2):217-221. doi: 10.1177/1747493019897870. Epub 2020 Jan 19. Erratum In: Int J Stroke. 2020 Jan 28;:1747493020905964.
  PMID: 31955707
  citation: Albini A, Malavasi VL, Vitolo M, Imberti JF, Marietta M, Lip GYH, Boriani G. Long-term outcomes of postoperative atrial fibrillation following non cardiac surgery: A systematic review and metanalysis. Eur J Intern Med. 2021 Mar;85:27-33. doi: 10.1016/j.ejim.2020.12.018. Epub 2021 Jan 2.
  PMID: 33402281
  citation: Lopes LA, Agrawal DK. Post-Operative Atrial Fibrillation: Current Treatments and Etiologies for a Persistent Surgical Complication. J Surg Res (Houst). 2022;5(1):159-172. doi: 10.26502/jsr.10020209. Epub 2022 Mar 28.
  PMID: 35445200
  citation: Goulden CJ, Hagana A, Ulucay E, Zaman S, Ahmed A, Harky A. Optimising risk factors for atrial fibrillation post-cardiac surgery. Perfusion. 2022 Oct;37(7):675-683. doi: 10.1177/02676591211019319. Epub 2021 May 26.
  PMID: 34034586
  citation: Phan K, Ha HS, Phan S, Medi C, Thomas SP, Yan TD. New-onset atrial fibrillation following coronary bypass surgery predicts long-term mortality: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2015 Dec;48(6):817-24. doi: 10.1093/ejcts/ezu551. Epub 2015 Jan 18.
  PMID: 25602053
  citation: Baig MM, GholamHosseini H, Moqeem AA, Mirza F, Linden M. A Systematic Review of Wearable Patient Monitoring Systems - Current Challenges and Opportunities for Clinical Adoption. J Med Syst. 2017 Jul;41(7):115. doi: 10.1007/s10916-017-0760-1. Epub 2017 Jun 19.
  PMID: 28631139
  citation: Tison GH, Sanchez JM, Ballinger B, Singh A, Olgin JE, Pletcher MJ, Vittinghoff E, Lee ES, Fan SM, Gladstone RA, Mikell C, Sohoni N, Hsieh J, Marcus GM. Passive Detection of Atrial Fibrillation Using a Commercially Available Smartwatch. JAMA Cardiol. 2018 May 1;3(5):409-416. doi: 10.1001/jamacardio.2018.0136.
  PMID: 29562087
  citation: Chandrasekaran R, Katthula V, Moustakas E. Patterns of Use and Key Predictors for the Use of Wearable Health Care Devices by US Adults: Insights from a National Survey. J Med Internet Res. 2020 Oct 16;22(10):e22443. doi: 10.2196/22443.
  PMID: 33064083
  citation: Nachman D, Gilan A, Goldstein N, Constantini K, Littman R, Eisenkraft A, Grossman E, Gepner Y. Twenty-Four-Hour Ambulatory Blood Pressure Measurement Using a Novel Noninvasive, Cuffless, Wireless Device. Am J Hypertens. 2021 Nov 20;34(11):1171-1180. doi: 10.1093/ajh/hpab095.
  PMID: 34143867
  responsible party type: Principal Investigator
  investigator affiliation: University of Sao Paulo
  investigator full name: Fabio Biscegli Jatene
  investigator title: MD, PhD
  provided document: 
  provided document: 